Приказ основних података о документу

dc.creatorCavić, Milena
dc.creatorKrivokuca, Ana
dc.creatorBoljević, Ivana
dc.creatorBrotto, Ksenija
dc.creatorJovanović, Katarina
dc.creatorTanić, Miljana
dc.creatorFilipović, Lana
dc.creatorZec, Manja M.
dc.creatorMalisić, Emma
dc.creatorJanković, Radmila
dc.creatorRadulović, Siniša
dc.date.accessioned2021-04-20T12:48:09Z
dc.date.available2021-04-20T12:48:09Z
dc.date.issued2016
dc.identifier.issn1107-0625
dc.identifier.urihttp://rimi.imi.bg.ac.rs/handle/123456789/712
dc.description.abstractPurpose: Pharmacogenetics is a study of possible mechanism by which an individual's response to drugs is genetically determined by variations in their DNA sequence. The aim of pharmacogenetics is to identify the optimal drug and dose for each individual based on their genetic constitution, i.e. to individualize drug treatment. This leads to achieving the maximal therapeutic response for each patient, while reducing adverse side effects of therapy and the cost of treatment. A centralized pharmacogenetics service was formed at the Institute for Oncology and Radiology of Serbia (IORS) with the aim to provide a personalized approach to cancer treatment of Serbian patients. Methods: Analyses of KRAS mutations in metastatic colorectal cancer, EGFR mutations in advanced non-small cell lung cancer, CYP2D6 polymorphism in breast cancer, DPD polymorphism in colorectal cancer and MTHFR polymorphism in osteosarcoma have been performed by real time polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (PCR-RFLP). Results: Mutation testing analyses were successful for 1694 KRAS samples and 1821 EGFR samples, while polymorphism testing was successful for 9 CYP2D6 samples, 65 DPD samples and 35 MTHFR samples. Conclusions: Pharmacogenetic methods presented in this paper provide cancer patients in Serbia the best possible choice of treatment at the moment.en
dc.publisherBalkan Union of Oncology (B.U.ON.)
dc.relationinfo:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/41026/RS//
dc.rightsrestrictedAccess
dc.sourceJournal of BUON
dc.subjectEGFRen
dc.subjectKRASen
dc.subjectpersonalized therapyen
dc.subjectpharmacogeneticsen
dc.titlePharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbiaen
dc.typearticle
dc.rights.licenseARR
dc.citation.epage1295
dc.citation.issue5
dc.citation.other21(5): 1287-1295
dc.citation.rankM23
dc.citation.spage1287
dc.citation.volume21
dc.identifier.pmid27837635
dc.identifier.rcubhttps://hdl.handle.net/21.15107/rcub_rimi_712
dc.identifier.wos000388782200033
dc.type.versionpublishedVersion


Документи

ДатотекеВеличинаФорматПреглед

Уз овај запис нема датотека.

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу